Company news
Aker Biomarine Asa (OSL:AKBM) news
Aker Biomarine Asa news releases on 6ix. Latest, Sep 11, 2026: Aker BioMarine ASA: Disclosure of large shareholding and mandatory notification of trade
Press releases & updates
Aker BioMarine ASA: Disclosure of large shareholding and mandatory notification of trade
September 11, 2026
Aker BioMarine ASA: Extraordinary general meeting held - merger plan approved and condition for completion of cash offer fulfilled
August 17, 2026
Aker BioMarine : Result in optional cash offer to the shareholders of Aker BioMarine ASA
July 31, 2026
Aker BioMarine ASA: Mandatory Notification of Trade
July 28, 2026
Aker BioMarine ASA - Notice of Extraordinary General Meeting
July 17, 2026
Aker BioMarine ASA: Proposed merger and optional cash offer
July 16, 2026
Aker BioMarine : reports continued krill oil momentum in Q2, with revenues up 21%
July 10, 2026
Aker BioMarine ASA - Invitation to presentation of the second quarter 2026 results
July 9, 2026
Engie, Aker BioMarine Sign Agreement For Renewable Energy Delivery
June 17, 2026
Aker Biomarine Secures Lysoveta Contract
May 6, 2026
AKBM: Q1 revenue up 13% to $57.3M, with record krill oil sales and improved EBITDA margin
April 30, 2026
Aker BioMarine ASA: Minutes of Annual General Meeting
April 28, 2026
Aker BioMarine ASA - Invitation to presentation of the first quarter 2026 results
April 27, 2026
Aker BioMarine : Earnings Reports (AKBM Annual Report 2025 1)
March 27, 2026
Aker BioMarine ASA - Notice of Annual General Meeting
March 26, 2026
Aker BioMarine ASA - Annual Report 2025
March 26, 2026
AKBM: Strong Q4 driven by Human Health Ingredients growth and strategic focus on 2026 expansion
February 12, 2026
Aker BioMarine ASA - Invitation to presentation of the fourth quarter 2025 results
February 11, 2026
Financial calendar
December 10, 2025
MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER
November 5, 2025
AKBM: Strong growth in core segments, improved margins, and robust outlook despite tariff risks
October 31, 2025
Aker BioMarine ASA - Invitation to presentation of the third quarter 2025 results
October 28, 2025
AKBM: Q2 2025 delivered double-digit growth, margin expansion, and robust segment performance
July 11, 2025
AKBM: Q1 2025 delivered strong revenue and EBITDA growth, with robust outlook and mitigated risks
April 30, 2025
AKBM: Q4 revenue up 7% and EBITDA nearly tripled, driven by Human Health Ingredients growth
February 12, 2025
AKBM: Net profit surged to USD 207.5 million in Q3 2024 after the Feed Ingredients sale
November 1, 2024
AKBM: Q2 revenue up 6%, Feed Ingredient sold for $590M, extraordinary dividend planned
July 12, 2024